Veloxis Pharmaceuticals A/S - Correction: US FDA Accepts Veloxis' New Drug ... Wall Street Journal Envarsus(R) is Veloxis' once-daily tacrolimus based on the company's proprietary MELTDOSE technology. Key points: -- FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of October 30, 2014 -- The NDA was submitted to the ... Correction: U.S. FDA Accepts Veloxis' New Drug Application for EnvarsusĀ® for ... |
